This article discusses 10 expert tips for mitigating dry mouth, a common symptom of Sjögren’s disease & other rheumatic conditions.
Guidelines for ILD in Systemic Autoimmune Rheumatic Disease
Over 50% of patients with systemic sclerosis (SSc) develop interstitial lung disease (ILD), and rheumatologists have long recognized this major cause of morbidity and mortality.1 Sindhu R. Johnson, MD, PhD, professor of medicine at the University of Toronto, Canada, and director of the Toronto Scleroderma Program, notes that more recent studies have increased our awareness…
Dazodalibep for Sjögren’s Disease
St.Clair et al. found that patients with Sjögren’s disease treated with dazodalibep experienced greater improvement in key symptoms of dryness, fatigue & pain than patients who received placebo.
New Review Article Explores Endotyping, B Cells & More
A case-based review examines B cells in Sjögren’s disease, the use of endotyping for patient stratification & prognostication, & lymphoma risk.
A Sound Diagnosis for Glandular Swelling
In this case study, ultrasonography proves useful for excluding a diagnosis of Sjögren’s disease, leading to a correct diagnosis of IgG4-RD.
Small Fiber Neuropathy: What the Rheumatologist Needs to Know
An expert on peripheral neuropathy shares his practical approach to the diagnosis & management of small fiber neuropathy
New Discoveries in Sjögren’s Disease Hold Promise
This article discusses advances in the diagnosis & treatment of Sjögren’s disease, as well as practical diagnostic tips for clinicians.
Promising Phase 2 Results for Efgartigimod alfa-fcab in Adults with Primary Sjögren’s Disease
A study from Peene et al. found that patients with primary Sjögren’s disease experienced significant improvements in systemic disease activity and symptoms when treated with intravenous efgartigimod alfa-fcab.
New Discoveries in Sjögren’s Disease
Although dryness and other symptoms of Sjögren’s disease continue to vex patients, the prospect of new treatments and a recent name change demonstrate advances in patient care.
Nipocalimab Receives Breakthrough Therapy Status for Sjögren’s Disease
Nipocalimab, an investigational monoclonal antibody that blocks FcRn and reduces levels of circulating immunoglobulin G (IgG) antibodies, has received the FDA’s breakthrough therapy designation for the treatment of Sjögren’s disease.
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 10
- Next Page »